201 related articles for article (PubMed ID: 37368936)
1. Mathematical modeling the order of driver gene mutations in colorectal cancer.
Li L; Hu Y; Xu Y; Tang S
PLoS Comput Biol; 2023 Jun; 19(6):e1011225. PubMed ID: 37368936
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
3. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.
Palacio-Rúa KA; Isaza-Jiménez LF; Ahumada-Rodríguez E; Muñetón-Peña CM
Rev Gastroenterol Mex; 2014; 79(2):79-89. PubMed ID: 24861525
[TBL] [Abstract][Full Text] [Related]
4. Mathematical model of colorectal cancer initiation.
Paterson C; Clevers H; Bozic I
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20681-20688. PubMed ID: 32788368
[TBL] [Abstract][Full Text] [Related]
5. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.
He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M
World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
7. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
Du L; Kim JJ; Shen J; Chen B; Dai N
Oncotarget; 2017 Mar; 8(13):22175-22186. PubMed ID: 28077799
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer with and without microsatellite instability involves different genes.
Salahshor S; Kressner U; Pâhlman L; Glimelius B; Lindmark G; Lindblom A
Genes Chromosomes Cancer; 1999 Nov; 26(3):247-52. PubMed ID: 10502323
[TBL] [Abstract][Full Text] [Related]
9. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
[TBL] [Abstract][Full Text] [Related]
10. Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.
Hendricks A; Rosenstiel P; Hinz S; Burmeister G; Röcken C; Boersch K; Schafmayer C; Becker T; Franke A; Forster M
BMC Med Genet; 2020 Jan; 21(1):3. PubMed ID: 31900123
[TBL] [Abstract][Full Text] [Related]
11. Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports.
Okada S; Hata K; Kawai K; Yamamoto Y; Tanaka T; Nishikawa T; Sasaki K; Kaneko M; Emoto S; Murono K; Nozawa H
Medicine (Baltimore); 2019 Mar; 98(12):e14781. PubMed ID: 30896620
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations in colorectal cancer from Tunisia: relationships with site of tumor origin, microsatellite instability and KRAS mutations.
Aissi S; Buisine MP; Zerimech F; Kourda N; Moussa A; Manai M; Porchet N
Mol Biol Rep; 2014 Mar; 41(3):1807-13. PubMed ID: 24443225
[TBL] [Abstract][Full Text] [Related]
13. Genomic landscape of pathogenic mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian colorectal cancer.
Marbun VMG; Erlina L; Lalisang TJM
PLoS One; 2022; 17(6):e0267090. PubMed ID: 35709138
[TBL] [Abstract][Full Text] [Related]
14. Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers.
Liu X; Xu X; Wu Z; Shan Q; Wang Z; Wu Z; Ding X; Huang W; Wang Z
Front Immunol; 2022; 13():961350. PubMed ID: 36172359
[TBL] [Abstract][Full Text] [Related]
15. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
16. Combined Mutation of
Sakai E; Nakayama M; Oshima H; Kouyama Y; Niida A; Fujii S; Ochiai A; Nakayama KI; Mimori K; Suzuki Y; Hong CP; Ock CY; Kim SJ; Oshima M
Cancer Res; 2018 Mar; 78(5):1334-1346. PubMed ID: 29282223
[TBL] [Abstract][Full Text] [Related]
17. Impact of a haplotype (composed of the APC, KRAS, and TP53 genes) on colorectal adenocarcinoma differentiation and patient prognosis.
Peng X; Zhang T; Jia X; Wang T; Lin H; Li G; Li R; Zhang A
Cancer Genet; 2022 Nov; 268-269():115-123. PubMed ID: 36288643
[TBL] [Abstract][Full Text] [Related]
18. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
[TBL] [Abstract][Full Text] [Related]
19. Coaltered
Datta J; Smith JJ; Chatila WK; McAuliffe JC; Kandoth C; Vakiani E; Frankel TL; Ganesh K; Wasserman I; Lipsyc-Sharf M; Guillem J; Nash GM; Paty PB; Weiser MR; Saltz LB; Berger MF; Jarnagin WR; Balachandran V; Kingham TP; Kemeny NE; Cercek A; Garcia-Aguilar J; Taylor BS; Viale A; Yaeger R; Solit DB; Schultz N; D'Angelica MI
Clin Cancer Res; 2020 Mar; 26(5):1077-1085. PubMed ID: 31719050
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations of the APC, KRAS, and TP53 genes in nonpolypoid colorectal adenomas.
van Wyk R; Slezak P; Hayes VM; Buys CH; Kotze MJ; de Jong G; Rubio C; Dolk A; Jaramillo E; Koizumi K; Grobbelaar JJ
Genes Chromosomes Cancer; 2000 Feb; 27(2):202-8. PubMed ID: 10612810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]